Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 30, 2013

View Archived Issues

Researchers at Roche present new Mdm2 inhibitors for cancer

Eli Lilly reports topline results from two global phase III ramucirumab studies

Phase I results show promising oncolytic activity for the anti-HB-EGF antibody U3-1565

NovaDigm Therapeutics begins phase Ib/IIa trial of NDV-3 candidiasis vaccine

Researchers from PharmaMar present first-in-human results for PM-060184

CRLX-101 safely combined with Avastin in phase Ib/IIa trial in renal cell carcinoma

Exelixis meets enrollment target in phase III COMET-1 trial

Neuropore Therapies discloses novel agents for neurodegenerative diseases

Nektar reports preliminary topline results from phase II NKTR-181 trial

Korean researchers patent new c-Met inhibitors

4SC Discovery grants Panoptes right to develop novel compound for severe eye diseases

Scientists at FibroGen synthesize novel PHD1 inhibitors

Bayer files for approval of Nexavar for treatment of thyroid cancer in Japan

FDA grants orphan drug designation to Zalicus' Z-160 for management of postherpetic neuralgia

New HIV integrase inhibitors disclosed by Bristol-Myers Squibb

Researchers at Dr. Reddy's Laboratories divulge new KOR agonists

Long-acting GLP-1 analogue shows promise in diabetic mice

EMA accepts olaparib MAA for review

FDA approves new dosing for CSL Behring's immunoglobulin G replacement therapy

Bioheart reports preliminary data from phase I ANGEL trial

FDA grants Titan Pharmaceuticals meeting regarding Probuphine NDA

Durata Therapeutics submits NDA in U.S. for dalbavancin

MAA filing for naloxegol for opioid-induced constipation accepted by EMA

Novartis files application for ruxolitinib in Japan

Axerion Therapeutics' prion protein program selected for NIH support

One-step genetic engineering of conditional transgenic mouse models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Anticancer drug exerts potent HIV antiviral effects
BioWorld Science
A new isoform of proliferating cell nuclear antigen (PCNA) – cancer-associated PCNA (caPCNA) – that is specifically expressed in cancer tissues has been reported....